Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction.

Shigeatsu Endo, Nobuhiro Sato, Yasunori Yaegashi, Yasushi Suzuki, Masahiro Kojika, Yasuhiko Yamada, Yuki Yoshida, Toshihide Nakadate, Hidehiko Aoki, Yoshihiro Inoue

Journal: Research communications in molecular pathology and pharmacology 2007;119(1-6):53-65

PMID: 17974096

View on PubMed

Abstract

Sivelestat sodium hydrate (sivelestat) is a selective inhibitor of polymorphonuclear leukocyte elastase (PMN-E). We administered sivelestat to patients with septic acute lung injury (ALI) to examine its usefulness. The primary endpoints in the study were the duration of artificial ventilation and pulmonary oxygenation ability, and the secondary endpoints were mortality and the concentrations of PMN-E, SP-D, TNF-alpha and IL-8 in blood. In the sivelestat group, the duration of artificial ventilation, pulmonary oxygenation ability, and the blood PMN-E, SP-D, TNF-alpha and IL-8 concentrations decreased significantly. Administration of sivelestat was found to reduce alveolar dysfunction and improve respiratory function, and it was suggested that early administration might be useful.

Address: Department of Critical Care Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan. [email protected]

MeSH Terms: Acute Disease, Adolescent, Adult, Aged, Glycine, Humans, Interleukin-8, Leukocyte Elastase, Leukocytes, Middle Aged, Oxygen, Pulmonary Circulation, Pulmonary Surfactant-Associated Protein D, Respiration, Artificial, Serine Proteinase Inhibitors, Sulfonamides, Survival Analysis, Systemic Inflammatory Response Syndrome, Treatment Outcome, Tumor Necrosis Factor-alpha